Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women
Older women with aggressive breast cancer achieve similar survival rates as younger women when treated comparably, challenging age-based treatment limitations.
Analysis of 4,246 mTNBC patients from the UNICANCER ESME national real-world cohort showed comparable median overall survival between older (≥70 years, n=987) and younger (40-69 years, n=3,259) women despite marked treatment disparities — older patients less likely to receive chemotherapy or targeted therapy. These findings demonstrate that older women with mTNBC, a highly underrepresented group in clinical trials, can achieve similar outcomes and warrant better inclusion in research and new therapy evaluation.
What the study was
- Study design
- Retrospective cohort (national real-world database)
- Population
- Women with metastatic TNBC: older (≥70 years, n=987) vs younger (40-69 years, n=3259)
- Sample size
- 4246
- Category
- Public Health
- Maturity
- Validated
- Journal
- The Breast
Why it surfaced
Large national real-world cohort (n=4,246) addressing underrepresentation of older women in mTNBC trials; near-equipoise survival data despite treatment disparity is practice-relevant; ESME cohort national French database with high credibility
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.